Publications by authors named "David B Whitman"

Claim this Profile
A
Amide- and bis-amide-linked highly potent and broadly active antifungal agents for the treatment of invasive fungal infections- towards the discovery of pre-clinical development candidate FC12406.
Simon D P Baugh, Anna Chaly, Damian G Weaver, David B Whitman, Jeffrey C Pelletier

Med Chem Res· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties.
Paul J Coleman, John D Schreier, Christopher D Cox, Michael J Breslin, David B Whitman

ChemMedChem· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.
Christopher D Cox, Michael J Breslin, David B Whitman, John D Schreier, Georgia B McGaughey

J Med Chem· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an n,n-disubstituted-1,4-diazepane scaffold that promotes sleep in rats.
David B Whitman, Christopher D Cox, Michael J Breslin, Karen M Brashear, John D Schreier

ChemMedChem· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conformational analysis of N,N-disubstituted-1,4-diazepane orexin receptor antagonists and implications for receptor binding.
Christopher D Cox, Georgia B McGaughey, Michael J Bogusky, David B Whitman, Richard G Ball

Bioorg Med Chem Lett· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer.
Christopher D Cox, Paul J Coleman, Michael J Breslin, David B Whitman, Robert M Garbaccio

J Med Chem· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinesin spindle protein (KSP) inhibitors. Part V: discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by beta-fluorination to overcome cellular efflux by P-glycoprotein.
Christopher D Cox, Michael J Breslin, David B Whitman, Paul J Coleman, Robert M Garbaccio

Bioorg Med Chem Lett· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinesin spindle protein (KSP) inhibitors. Part 4: Structure-based design of 5-alkylamino-3,5-diaryl-4,5-dihydropyrazoles as potent, water-soluble inhibitors of the mitotic kinesin KSP.
Christopher D Cox, Maricel Torrent, Michael J Breslin, Brenda J Mariano, David B Whitman

Bioorg Med Chem Lett· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonpeptide alpha V beta 3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backbone.
David B Whitman, Ben C Askew, Le T Duong, Carmen Fernandez-Metzler, Wasyl Halczenko

Bioorg Med Chem Lett· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimetics.
Paul J Coleman, Ben C Askew, John H Hutchinson, David B Whitman, James J Perkins

Bioorg Med Chem Lett· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonpeptide alpha(v)beta(3) antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptide.
Robert S Meissner, James J Perkins, Le T Duong, George D Hartman, William F Hoffman, David B Whitman

Bioorg Med Chem Lett· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis